All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LY1350 | Anti-GPRASP2 (698742) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 698742 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY1351 | Anti-GPRASP2 (14L463) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 14L463 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY1352 | Anti-GPRASP2 (6M51) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 6M51 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY1353 | Anti-GPRASP2 (7H70) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7H70 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY1354 | Anti-GPRASP2 (MM0304-6M51) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | MM0304-6M51 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY2990 | Anti-GPRASP2(698742) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 698742 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY2991 | Anti-GPRASP2(14L463) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 14L463 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY2992 | Anti-GPRASP2(6M51) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6M51 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY2993 | Anti-GPRASP2(7H70) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7H70 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-LY2994 | Anti-GPRASP2(MM0304-6M51) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MM0304-6M51 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION